Please assess the completion status of the following clinical trial:

Trial Title: A Study of Esomeplazole (D961H) in Japanese Paediatric Patients With Reflux Esophagitis, Gastric Ulcer or Duodenal Ulcer

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~For healed reflux esophagitis study~* Endoscopically verified reflux esophagitis, Grade A or higher according to the Los Angels classification as judged by central evaluation committee.~For prevention of gastric ulcer or duodenal ulcer recurrence study~* Patients with documented medical history of gastric ulser or duodenal ulser diagnosis based on upper gastrointestinal symptoms, fecal occult blood, esophagogastroduodenoscopy findings, etc.~Exclusion Criteria:~* Patients less than 10 kg in weight.~* Use of any other investigational compounds or participations in another clinical trial within 4 weeks prior to the enrolment.~* Significant clinical illness within 4 weeks prior to the informed consent~* Previous total gastrectomy.~* Presence of hepatic diseases or other conditions that could interfere with evaluation of the study as judged by investigators. etc.

- Gender: ALL
- Minimum Age: 1 Year
- Maximum Age: 14 Years
- Healthy Volunteers: f

Study Arms:
- Group1 (Type: EXPERIMENTAL): Initial healing phase (8 weeks), D961H 10 mg once-daily; Maintenance phase (24 or 44 weeks), D961H 10 mg once-daily
- Group2 (Type: EXPERIMENTAL): Initial healing phase (8 weeks), D961H 20 mg once-daily; Maintenance phase (24 or 44 weeks) starts with D961H 10 mg once-daily and may be increased to 20 mg once-daily based on investigator's discretion
- Group3 (Type: EXPERIMENTAL): D961H 10 mg once-daily (32 or 52 weeks)
- Group4 (Type: EXPERIMENTAL): D961H starts with 10 mg once-daily, and may be increased to 20 mg once-daily based on investigator's discretion (32 or 52 weeks)

Based on this trial design, predict the completion outcome and termination type (if applicable).